Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $78.4 million.

  • Collegium Pharmaceutical's Cash from Operations rose 97163.02% to $78.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $290.9 million, marking a year-over-year increase of 5021.07%. This contributed to the annual value of $205.0 million for FY2024, which is 2539.37% down from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Cash from Operations stood at $78.4 million, which was up 97163.02% from $72.4 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Cash from Operations' 5-year high stood at $99.7 million during Q2 2023, with a 5-year trough of -$25.3 million in Q1 2022.
  • Over the past 5 years, Collegium Pharmaceutical's median Cash from Operations value was $55.4 million (recorded in 2025), while the average stood at $48.1 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Cash from Operations crashed by 22306.76% in 2022, and later surged by 97163.02% in 2025.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Cash from Operations stood at $36.2 million in 2021, then surged by 83.23% to $66.3 million in 2022, then increased by 10.57% to $73.3 million in 2023, then rose by 15.42% to $84.6 million in 2024, then fell by 7.33% to $78.4 million in 2025.
  • Its last three reported values are $78.4 million in Q3 2025, $72.4 million for Q2 2025, and $55.4 million during Q1 2025.